RVPH vs. IGMS, PDSB, QNTM, ANRO, VHAQ, ASRT, STRO, PYRGF, ICCC, and ACHL
Should you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include IGM Biosciences (IGMS), PDS Biotechnology (PDSB), Quantum Biopharma (QNTM), Alto Neuroscience (ANRO), Viveon Health Acquisition (VHAQ), Assertio (ASRT), Sutro Biopharma (STRO), PyroGenesis Canada (PYRGF), ImmuCell (ICCC), and Achilles Therapeutics (ACHL). These companies are all part of the "pharmaceutical products" industry.
Reviva Pharmaceuticals vs. Its Competitors
Reviva Pharmaceuticals (NASDAQ:RVPH) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.
63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 27.2% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 57.0% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Reviva Pharmaceuticals has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.
In the previous week, IGM Biosciences had 2 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 4 mentions for IGM Biosciences and 2 mentions for Reviva Pharmaceuticals. IGM Biosciences' average media sentiment score of 0.51 beat Reviva Pharmaceuticals' score of 0.00 indicating that IGM Biosciences is being referred to more favorably in the news media.
Reviva Pharmaceuticals presently has a consensus price target of $9.00, indicating a potential upside of 2,289.80%. IGM Biosciences has a consensus price target of $5.50, indicating a potential upside of 313.53%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Reviva Pharmaceuticals is more favorable than IGM Biosciences.
Reviva Pharmaceuticals has higher earnings, but lower revenue than IGM Biosciences. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
Reviva Pharmaceuticals has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,417.79%. Reviva Pharmaceuticals' return on equity of 0.00% beat IGM Biosciences' return on equity.
Summary
Reviva Pharmaceuticals beats IGM Biosciences on 9 of the 16 factors compared between the two stocks.
Get Reviva Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Reviva Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RVPH) was last updated on 7/9/2025 by MarketBeat.com Staff
Free RVPH Stock Alerts